NEW YORK, June 13, 2022 The Insight Partners published latest research study on "Branded Generics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Therapeutic Application, Distribution Channel, Drug Class, and Formulation Type", the global branded generics market is expected to grow from $235.86 billion in 2022 to $414.99 billion by 2028; it is estimated to grow at a CAGR of 9.9...
The increase in the Severe Asthma market size is a direct consequence of the expected launch of potential therapies an increase in the diagnosed prevalent population of Severe Asthma and increasing demand for personalized therapies.
SAN FRANCISCO, June 7, 2022 The global active pharmaceutical ingredients market size is expected to reach USD 353.0 billion by 2030, expanding at a compound annual growth rate of 6.0% during the forecast period, according to a new report by Grand View Research, Inc. The market is driven by the growth of the biopharmaceutical sector, advancements in active pharmaceutical Ingredients manufacturi...
NEW YORK, June 6, 2022 According to the market research report published by P&S Intelligence, in 2021, the revenue of the tangential flow filtration market was $1,237.6 million, which is likely to progress at a 12.8% CAGR from 2021 to 2030 and reach $3,667.2 million.
LONDON, June 3, 2022 The Idiopathic Pulmonary Fibrosis Market size is expected to reach USD 5326.8 Million by 2028, registering to accelerate at a 7.1% CAGR, according to the most recent study by Brandessence Market Research & Consulting Pvt ltd. The Global Idiopathic Pulmonary Fibrosis Market size was Valued at USD 3295.6 Million in 2021. Increasing geriatric population, rising smokers populat...
The increment in Checkpoint Inhibitor Refractory Cancer market size is due to high potency against cancer cells, increase in R&D activity, rise in the cases of types of cancers, where checkpoint inhibitors are in use, expected commercial success of upcoming therapies which are going to resolve the issue of primary resistance, along with a hike in the usage of approved Checkpoint Inhibitor thera...
The increase in the LAG 3 Next Generation Immunotherapy market size is a direct consequence of the expected entry of premium LAG-3 drugs and their readily uptake, increase in cancer incident cases, along with PD-1/PD-L1 relapsed/refractory pool, and label-expansion in multiple cancer types.
News, commentary and research reports are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.
PDF’s require Adobe® Reader® and will open in a new window.
Log In Required
Line of Credit Log In Required